News|Articles|March 15, 2020

A Practical Approach to Pharmacopoeia Compliance

Author(s)J. Mark Wiggins, Joseph A. Albanese

This article presents a case study at the intersection of monograph development and compliance.

External Link - PTebook0320_024-032_PharmacopeiaCompendia_Part10_PracticalApproach.pdf

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

PharmTech Weekly Roundup—June 19, 2026

BySusan Haigney

June 19th 2026

First generic of single-dose flu drug approved by the FDA

Why the First Generic Single-Dose Flu Antiviral Approval Matters

ByZachary Zubulake

June 18th 2026

Sustainable eco concept with green globe floating in clear glass beaker symbolizing healthcare and pharma innovation for better future | Image Credit: ©newlifestock -stock.adobe.com

Sustainability by Design: Re-Imagining Amorphous Dispersion Manufacturing

ByElizabeth Hickman

June 18th 2026

Duloxetine recalled over heightend levels of nitrosamine

FDA Duloxetine Recall Highlights Generic Manufacturing Quality Gaps

ByZachary Zubulake

June 17th 2026

Pharmacovigilance (PV or PhV), also known as drug safety, is the pharmacological science to detection, monitoring, and prevention of adverse effects with pharmaceutical product. Medical safety concept | Image Credit: ©Joel bubble ben -stock.adobe.com

Reimagining Signal Management: How Autonomous Pharmacovigilance Could Render Reporting Timelines a Thing of the Past

ByLucinda Smith

June 16th 2026

A Practical Approach to Pharmacopoeia Compliance

Related Content

PharmTech Weekly Roundup—June 19, 2026

Why the First Generic Single-Dose Flu Antiviral Approval Matters

Sustainability by Design: Re-Imagining Amorphous Dispersion Manufacturing

FDA Duloxetine Recall Highlights Generic Manufacturing Quality Gaps

Reimagining Signal Management: How Autonomous Pharmacovigilance Could Render Reporting Timelines a Thing of the Past

Trending on Pharmaceutical Technology

FDA Duloxetine Recall Highlights Generic Manufacturing Quality Gaps

Germany Pharma Tariff Threat: What Manufacturers Need to Know

PharmTech Weekly Roundup—June 19, 2026

Is Compliant AI in Pharma Even Possible? The Search for an Honest Answer

Why Pharma Dealmaking Slowed in Q1 2026 and What Is Coming Next